Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.
Identifieur interne : 000487 ( PubMed/Corpus ); précédent : 000486; suivant : 000488Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.
Auteurs : Mohammad Amin Behzadi ; Victor H. Leyva-GradoSource :
- Frontiers in microbiology [ 1664-302X ] ; 2019.
Abstract
Emergence and re-emergence of respiratory virus infections represent a significant threat to global public health, as they occur seasonally and less frequently (such as in the case of influenza virus) as pandemic infections. Some of these viruses have been in the human population for centuries and others had recently emerged as a public health problem. Influenza viruses have been affecting the human population for a long time now; however, their ability to rapidly evolve through antigenic drift and antigenic shift causes the emergence of new strains. A recent example of these events is the avian-origin H7N9 influenza virus outbreak currently undergoing in China. Human H7N9 influenza viruses are resistant to amantadines and some strains are also resistant to neuraminidase inhibitors greatly limiting the options for treatment. Respiratory syncytial virus (RSV) may cause a lower respiratory tract infection characterized by bronchiolitis and pneumonia mainly in children and the elderly. Infection with RSV can cause severe disease and even death, imposing a severe burden for pediatric and geriatric health systems worldwide. Treatment for RSV is mainly supportive since the only approved therapy, a monoclonal antibody, is recommended for prophylactic use in high-risk patients. The Middle East respiratory syndrome coronavirus (MERS-CoV) is a newly emerging respiratory virus. The virus was first recognized in 2012 and it is associated with a lower respiratory tract disease that is more severe in patients with comorbidities. No licensed vaccines or antivirals have been yet approved for the treatment of MERS-CoV in humans. It is clear that the discovery and development of novel antivirals that can be used alone or in combination with existing therapies to treat these important respiratory viral infections are critical. In this review, we will describe some of the novel therapeutics currently under development for the treatment of these infections.
DOI: 10.3389/fmicb.2019.01327
PubMed: 31275265
Links to Exploration step
pubmed:31275265Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.</title><author><name sortKey="Behzadi, Mohammad Amin" sort="Behzadi, Mohammad Amin" uniqKey="Behzadi M" first="Mohammad Amin" last="Behzadi">Mohammad Amin Behzadi</name><affiliation><nlm:affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Leyva Grado, Victor H" sort="Leyva Grado, Victor H" uniqKey="Leyva Grado V" first="Victor H" last="Leyva-Grado">Victor H. Leyva-Grado</name><affiliation><nlm:affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31275265</idno><idno type="pmid">31275265</idno><idno type="doi">10.3389/fmicb.2019.01327</idno><idno type="wicri:Area/PubMed/Corpus">000487</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000487</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.</title><author><name sortKey="Behzadi, Mohammad Amin" sort="Behzadi, Mohammad Amin" uniqKey="Behzadi M" first="Mohammad Amin" last="Behzadi">Mohammad Amin Behzadi</name><affiliation><nlm:affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Leyva Grado, Victor H" sort="Leyva Grado, Victor H" uniqKey="Leyva Grado V" first="Victor H" last="Leyva-Grado">Victor H. Leyva-Grado</name><affiliation><nlm:affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Frontiers in microbiology</title><idno type="ISSN">1664-302X</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Emergence and re-emergence of respiratory virus infections represent a significant threat to global public health, as they occur seasonally and less frequently (such as in the case of influenza virus) as pandemic infections. Some of these viruses have been in the human population for centuries and others had recently emerged as a public health problem. Influenza viruses have been affecting the human population for a long time now; however, their ability to rapidly evolve through antigenic drift and antigenic shift causes the emergence of new strains. A recent example of these events is the avian-origin H7N9 influenza virus outbreak currently undergoing in China. Human H7N9 influenza viruses are resistant to amantadines and some strains are also resistant to neuraminidase inhibitors greatly limiting the options for treatment. Respiratory syncytial virus (RSV) may cause a lower respiratory tract infection characterized by bronchiolitis and pneumonia mainly in children and the elderly. Infection with RSV can cause severe disease and even death, imposing a severe burden for pediatric and geriatric health systems worldwide. Treatment for RSV is mainly supportive since the only approved therapy, a monoclonal antibody, is recommended for prophylactic use in high-risk patients. The Middle East respiratory syndrome coronavirus (MERS-CoV) is a newly emerging respiratory virus. The virus was first recognized in 2012 and it is associated with a lower respiratory tract disease that is more severe in patients with comorbidities. No licensed vaccines or antivirals have been yet approved for the treatment of MERS-CoV in humans. It is clear that the discovery and development of novel antivirals that can be used alone or in combination with existing therapies to treat these important respiratory viral infections are critical. In this review, we will describe some of the novel therapeutics currently under development for the treatment of these infections.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31275265</PMID><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-302X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Frontiers in microbiology</Title><ISOAbbreviation>Front Microbiol</ISOAbbreviation></Journal><ArticleTitle>Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.</ArticleTitle><Pagination><MedlinePgn>1327</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmicb.2019.01327</ELocationID><Abstract><AbstractText>Emergence and re-emergence of respiratory virus infections represent a significant threat to global public health, as they occur seasonally and less frequently (such as in the case of influenza virus) as pandemic infections. Some of these viruses have been in the human population for centuries and others had recently emerged as a public health problem. Influenza viruses have been affecting the human population for a long time now; however, their ability to rapidly evolve through antigenic drift and antigenic shift causes the emergence of new strains. A recent example of these events is the avian-origin H7N9 influenza virus outbreak currently undergoing in China. Human H7N9 influenza viruses are resistant to amantadines and some strains are also resistant to neuraminidase inhibitors greatly limiting the options for treatment. Respiratory syncytial virus (RSV) may cause a lower respiratory tract infection characterized by bronchiolitis and pneumonia mainly in children and the elderly. Infection with RSV can cause severe disease and even death, imposing a severe burden for pediatric and geriatric health systems worldwide. Treatment for RSV is mainly supportive since the only approved therapy, a monoclonal antibody, is recommended for prophylactic use in high-risk patients. The Middle East respiratory syndrome coronavirus (MERS-CoV) is a newly emerging respiratory virus. The virus was first recognized in 2012 and it is associated with a lower respiratory tract disease that is more severe in patients with comorbidities. No licensed vaccines or antivirals have been yet approved for the treatment of MERS-CoV in humans. It is clear that the discovery and development of novel antivirals that can be used alone or in combination with existing therapies to treat these important respiratory viral infections are critical. In this review, we will describe some of the novel therapeutics currently under development for the treatment of these infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Behzadi</LastName><ForeName>Mohammad Amin</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyva-Grado</LastName><ForeName>Victor H</ForeName><Initials>VH</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN272201400008C</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Microbiol</MedlineTA><NlmUniqueID>101548977</NlmUniqueID><ISSNLinking>1664-302X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MERS-coronavirus</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">novel therapeutic agents</Keyword><Keyword MajorTopicYN="N">respiratory syncytial virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>03</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>05</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31275265</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2019.01327</ArticleId><ArticleId IdType="pmc">PMC6594388</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pediatr Infect Dis J. 2000 Aug;19(8):786-90; discussion 802-4, 811-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10959759</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Soc Exp Biol Med. 1956 Jul;92(3):544-9</Citation><ArticleIdList><ArticleId IdType="pubmed">13359460</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2003 Nov;60(3):221-31</Citation><ArticleIdList><ArticleId IdType="pubmed">14638398</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2005 Mar;49(3):981-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15728892</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2005 Oct;68(1):18-26</Citation><ArticleIdList><ArticleId IdType="pubmed">16112208</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2006 Apr;50(4):1470-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16569867</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2007 Mar;51(3):845-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17194832</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2007 May 4;368(3):652-65</Citation><ArticleIdList><ArticleId IdType="pubmed">17362988</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2007 Sep;51(9):3346-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17576833</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2007 Sep 20;50(19):4572-84</Citation><ArticleIdList><ArticleId IdType="pubmed">17722899</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2007 Nov 15;196(10):1493-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18008229</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 Jan 31;451(7178):591-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18235503</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2008 Feb 28;51(4):875-96</Citation><ArticleIdList><ArticleId IdType="pubmed">18254606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Perinatol. 2008 Jul;28(7):511-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18368063</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2009 Apr;28(4):267-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19258920</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74</Citation><ArticleIdList><ArticleId IdType="pubmed">19442032</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2009 Aug 1;200(3):439-47</Citation><ArticleIdList><ArticleId IdType="pubmed">19545210</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2009 Oct 23;284(43):29798-808</Citation><ArticleIdList><ArticleId IdType="pubmed">19638339</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009 Nov 06;4(11):e7788</Citation><ArticleIdList><ArticleId IdType="pubmed">19893747</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Struct Mol Biol. 2009 Dec;16(12):1267-71</Citation><ArticleIdList><ArticleId IdType="pubmed">19898475</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2010 Jan;54(1):126-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19901093</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2009 Dec 15;200(12):1870-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19911992</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2010 Feb;65(2):275-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19942616</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2010 Feb;125(2):342-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20100768</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010 Feb 08;5(2):e9106</Citation><ArticleIdList><ArticleId IdType="pubmed">20161706</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 May 11;107(19):8800-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20421463</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2011 Feb;1808(2):522-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20451491</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2010 Nov;54(11):4534-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20823290</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2011 Jan;66(1):15-28</Citation><ArticleIdList><ArticleId IdType="pubmed">21097900</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2011 Mar 1;203(5):674-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21208913</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6739-44</Citation><ArticleIdList><ArticleId IdType="pubmed">21502533</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2011 Aug 12;333(6044):843-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21737702</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2012 Apr;94(1):103-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22429564</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2012 Dec 15;206(12):1844-51</Citation><ArticleIdList><ArticleId IdType="pubmed">23045618</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2012 Oct 04;17(40):20290</Citation><ArticleIdList><ArticleId IdType="pubmed">23078800</ArticleId></ArticleIdList></Reference><Reference><Citation>JAAPA. 2012 Oct;25(10):19-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23115865</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2013 Jan 16;5(1):211-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23325327</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Sep 26;501(7468):551-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23842494</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2013 Jul 17;14(1):93-103</Citation><ArticleIdList><ArticleId IdType="pubmed">23870317</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2013 Sep;13(9):752-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23891402</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Aug 29;369(9):884-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23923992</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2013 Oct;17(10):e792-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23993766</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2013 Oct;19(10):1313-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24013700</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Top Microbiol Immunol. 2013;372:3-38</Citation><ArticleIdList><ArticleId IdType="pubmed">24362682</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2014 Mar;20:42-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24406736</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2014;58(4):2045-51</Citation><ArticleIdList><ArticleId IdType="pubmed">24449767</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2014 Aug 1;210(3):435-40</Citation><ArticleIdList><ArticleId IdType="pubmed">24569063</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Mar 06;9(3):e90383</Citation><ArticleIdList><ArticleId IdType="pubmed">24603704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Am Thorac Soc. 2014 Mar;11(3):404-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24673696</ArticleId></ArticleIdList></Reference><Reference><Citation>Antivir Ther. 2015;20(1):87-91</Citation><ArticleIdList><ArticleId IdType="pubmed">24831606</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2014 May 14;15(5):644-51</Citation><ArticleIdList><ArticleId IdType="pubmed">24832457</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2014 Jul;14(7):609-18</Citation><ArticleIdList><ArticleId IdType="pubmed">24852376</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2014 Aug 14;57(15):6668-78</Citation><ArticleIdList><ArticleId IdType="pubmed">25019388</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2015 Jan 1;211(1):80-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25030060</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2014 Dec 1;59(11):1511-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25100864</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2015 Jan 15;211(2):249-57</Citation><ArticleIdList><ArticleId IdType="pubmed">25124927</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2015 Jan;89(1):512-22</Citation><ArticleIdList><ArticleId IdType="pubmed">25339762</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2015 Feb;59(2):1061-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25451059</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2015 Feb;59(2):1080-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25451060</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2015 Mar;59(3):1569-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25547360</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2015 Feb 26;58(4):1630-43</Citation><ArticleIdList><ArticleId IdType="pubmed">25574686</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2015 May;59(5):2607-17</Citation><ArticleIdList><ArticleId IdType="pubmed">25691635</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2015 Apr;125(4):1637-47</Citation><ArticleIdList><ArticleId IdType="pubmed">25751145</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2015 Jun;89(11):6117-20</Citation><ArticleIdList><ArticleId IdType="pubmed">25787284</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem Lett. 2015 May 1;25(9):1990-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25827523</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2015 Jul;70(7):2129-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25900158</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 May 26;10(5):e0126959</Citation><ArticleIdList><ArticleId IdType="pubmed">26010881</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2015 Sep 5;386(9997):995-1007</Citation><ArticleIdList><ArticleId IdType="pubmed">26049252</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2015 Jul;36:54-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26072036</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2015 Jul;21(7):1269-71</Citation><ArticleIdList><ArticleId IdType="pubmed">26080032</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2015 Jun 22;11(6):e1004995</Citation><ArticleIdList><ArticleId IdType="pubmed">26098424</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43</Citation><ArticleIdList><ArticleId IdType="pubmed">26124093</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Health. 2015 Jul 21;37:e2015033</Citation><ArticleIdList><ArticleId IdType="pubmed">26212508</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2015 Nov;59(11):7109-12</Citation><ArticleIdList><ArticleId IdType="pubmed">26324264</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2015 Nov;123:114-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26391974</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2015 Oct 05;60(1):6-13</Citation><ArticleIdList><ArticleId IdType="pubmed">26438495</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hosp Infect. 2015 Nov;91(3):188-96</Citation><ArticleIdList><ArticleId IdType="pubmed">26452615</ArticleId></ArticleIdList></Reference><Reference><Citation>J Heart Lung Transplant. 2016 Feb;35(2):213-21</Citation><ArticleIdList><ArticleId IdType="pubmed">26452996</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2015 Dec;41:3-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26482389</ArticleId></ArticleIdList></Reference><Reference><Citation>Antivir Ther. 2016;21(5):455-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26492219</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2015 Dec;15(12):1398-408</Citation><ArticleIdList><ArticleId IdType="pubmed">26511956</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2015 Nov 19;373(21):2048-58</Citation><ArticleIdList><ArticleId IdType="pubmed">26580997</ArticleId></ArticleIdList></Reference><Reference><Citation>Springerplus. 2015 Nov 19;4:709</Citation><ArticleIdList><ArticleId IdType="pubmed">26618098</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Chem Biol. 2016 Feb;12(2):87-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26641933</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2015 Dec 11;11(12):e1005318</Citation><ArticleIdList><ArticleId IdType="pubmed">26658574</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virus Erad. 2016;2(1):1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26866060</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2016 May;15(5):327-47</Citation><ArticleIdList><ArticleId IdType="pubmed">26868298</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2016 Feb 17;8(326):326ra21</Citation><ArticleIdList><ArticleId IdType="pubmed">26888429</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Microbiol. 2016 Mar 31;7:450</Citation><ArticleIdList><ArticleId IdType="pubmed">27065996</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2016 Apr 21;16:174</Citation><ArticleIdList><ArticleId IdType="pubmed">27097824</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2016 Aug;132:170-7</Citation><ArticleIdList><ArticleId IdType="pubmed">27321665</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2017 Jan;169:47-56</Citation><ArticleIdList><ArticleId IdType="pubmed">27373507</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2016 Aug 22;60(9):5437-44</Citation><ArticleIdList><ArticleId IdType="pubmed">27381392</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2016 Jul 28;166(3):596-608</Citation><ArticleIdList><ArticleId IdType="pubmed">27453466</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Bronconeumol. 2017 Jan;53(1):19-26</Citation><ArticleIdList><ArticleId IdType="pubmed">27519544</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2016 Dec;71(12):3340-3350</Citation><ArticleIdList><ArticleId IdType="pubmed">27585965</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 2017 Mar 1;127:1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">27659812</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Virus Res. 2016;96:245-286</Citation><ArticleIdList><ArticleId IdType="pubmed">27712626</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2016 Dec;136:45-50</Citation><ArticleIdList><ArticleId IdType="pubmed">27771390</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Rev. 2017 Jan;30(1):277-319</Citation><ArticleIdList><ArticleId IdType="pubmed">27903593</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Anti Infect Ther. 2017 Mar;15(3):269-275</Citation><ArticleIdList><ArticleId IdType="pubmed">27937060</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2017 Feb 23;61(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">27956428</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2017 May;11(3):240-246</Citation><ArticleIdList><ArticleId IdType="pubmed">28146320</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chest Med. 2017 Mar;38(1):139-153</Citation><ArticleIdList><ArticleId IdType="pubmed">28159156</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet J. 2017 Feb;220:75-79</Citation><ArticleIdList><ArticleId IdType="pubmed">28190501</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 2017 Nov;56(11):1331-1342</Citation><ArticleIdList><ArticleId IdType="pubmed">28238203</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Respir Med. 2017 Aug;11(8):609-615</Citation><ArticleIdList><ArticleId IdType="pubmed">28574729</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2017 Oct;75(4):378-379</Citation><ArticleIdList><ArticleId IdType="pubmed">28606432</ArticleId></ArticleIdList></Reference><Reference><Citation>One Health. 2016 Dec 23;3:11-16</Citation><ArticleIdList><ArticleId IdType="pubmed">28616497</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2017 Aug 1;216(3):356-365</Citation><ArticleIdList><ArticleId IdType="pubmed">28633457</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 2018 Mar;57(3):367-377</Citation><ArticleIdList><ArticleId IdType="pubmed">28639229</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463</Citation><ArticleIdList><ArticleId IdType="pubmed">28769016</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2017 Oct 24;61(11):</Citation><ArticleIdList><ArticleId IdType="pubmed">28807912</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Respir Med. 2017 Nov;11(11):901-912</Citation><ArticleIdList><ArticleId IdType="pubmed">28826284</ArticleId></ArticleIdList></Reference><Reference><Citation>Transplantation. 2018 Jan;102(1):119-126</Citation><ArticleIdList><ArticleId IdType="pubmed">28846559</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Biol Evol. 2017 Jul 1;9(7):1913-1924</Citation><ArticleIdList><ArticleId IdType="pubmed">28854600</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Microbiol. 2017 Sep;66(9):1261-1274</Citation><ArticleIdList><ArticleId IdType="pubmed">28855003</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Public Health. 2018 Jan - Feb;11(1):9-17</Citation><ArticleIdList><ArticleId IdType="pubmed">28864360</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Infect Dis. 2017 Oct 13;3(10):691-694</Citation><ArticleIdList><ArticleId IdType="pubmed">28892353</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2017 Nov;147:142-148</Citation><ArticleIdList><ArticleId IdType="pubmed">28986103</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2017 Nov;11(6):525-530</Citation><ArticleIdList><ArticleId IdType="pubmed">28990339</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Clin Immunol. 2017 Dec;13(12):1107-1119</Citation><ArticleIdList><ArticleId IdType="pubmed">29035131</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 2017 Dec;77(18):1935-1966</Citation><ArticleIdList><ArticleId IdType="pubmed">29143192</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Med. 2017 Dec;11(4):462-470</Citation><ArticleIdList><ArticleId IdType="pubmed">29159596</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2018 Jan;149:118-142</Citation><ArticleIdList><ArticleId IdType="pubmed">29162476</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem Lett. 2018 Jan 1;28(1):11-14</Citation><ArticleIdList><ArticleId IdType="pubmed">29173944</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2017 Nov 30;8(1):1877</Citation><ArticleIdList><ArticleId IdType="pubmed">29187732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoonoses Public Health. 2018 May;65(3):322-333</Citation><ArticleIdList><ArticleId IdType="pubmed">29239118</ArticleId></ArticleIdList></Reference><Reference><Citation>Antivir Ther. 2018;23(4):335-344</Citation><ArticleIdList><ArticleId IdType="pubmed">29244026</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2018 Apr;18(4):410-418</Citation><ArticleIdList><ArticleId IdType="pubmed">29329957</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2018 Sep;37(9):886-892</Citation><ArticleIdList><ArticleId IdType="pubmed">29373476</ArticleId></ArticleIdList></Reference><Reference><Citation>Trials. 2018 Jan 30;19(1):81</Citation><ArticleIdList><ArticleId IdType="pubmed">29382391</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2018 Feb 09;10(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">29425176</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoecon Open. 2018 Mar;2(1):53-61</Citation><ArticleIdList><ArticleId IdType="pubmed">29464672</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2018 Jul 2;218(3):347-354</Citation><ArticleIdList><ArticleId IdType="pubmed">29506129</ArticleId></ArticleIdList></Reference><Reference><Citation>Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618764483</Citation><ArticleIdList><ArticleId IdType="pubmed">29562753</ArticleId></ArticleIdList></Reference><Reference><Citation>Future Med Chem. 2018 Apr 1;10(8):851-862</Citation><ArticleIdList><ArticleId IdType="pubmed">29629834</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2018 Apr 24;9(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">29691337</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2018 Jul;155:76-88</Citation><ArticleIdList><ArticleId IdType="pubmed">29758235</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2018 Jun 22;36(27):3960-3966</Citation><ArticleIdList><ArticleId IdType="pubmed">29801998</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1817-1827</Citation><ArticleIdList><ArticleId IdType="pubmed">29876771</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2018 Jul 10;9:1547</Citation><ArticleIdList><ArticleId IdType="pubmed">30042762</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2018 Oct 24;62(11):</Citation><ArticleIdList><ArticleId IdType="pubmed">30150460</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2018 Sep 6;379(10):913-923</Citation><ArticleIdList><ArticleId IdType="pubmed">30184455</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hosp Infect. 2019 Jan;101(1):42-46</Citation><ArticleIdList><ArticleId IdType="pubmed">30240813</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2018 Sep 10;9:1946</Citation><ArticleIdList><ArticleId IdType="pubmed">30250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2018 Dec;160:109-117</Citation><ArticleIdList><ArticleId IdType="pubmed">30316915</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2019 Mar 1;74(3):654-662</Citation><ArticleIdList><ArticleId IdType="pubmed">30476172</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Microbiol. 2018 Dec 06;9:3026</Citation><ArticleIdList><ArticleId IdType="pubmed">30574137</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pediatr. 2019 Feb;178(2):131-138</Citation><ArticleIdList><ArticleId IdType="pubmed">30610420</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1970 Oct;6(4):556-8</Citation><ArticleIdList><ArticleId IdType="pubmed">5497902</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1997 Jan;99(1):93-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8989345</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000487 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000487 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:31275265
|texte= Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:31275265" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |